|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased expression of CYP17A1 mRNA] |
CTD |
PMID:32298659 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Dek |
DEK proto-oncogene |
decreases chemical synthesis |
ISO |
DEK protein results in decreased chemical synthesis of N(1)-methylnicotinamide |
CTD |
PMID:28558019 |
|
NCBI chr17:17,580,804...17,602,825
Ensembl chr17:17,580,843...17,602,808
|
|
G |
Lepr |
leptin receptor |
affects abundance |
ISO |
LEPR affects the abundance of N(1)-methylnicotinamide |
CTD |
PMID:20567778 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
EXP |
N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased secretion of LHB protein] |
CTD |
PMID:32298659 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Nampt |
nicotinamide phosphoribosyltransferase |
multiple interactions |
EXP |
N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased expression of NAMPT mRNA] |
CTD |
PMID:32298659 |
|
NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
EXP |
N(1)-methylnicotinamide results in increased expression of PTGS2 mRNA |
CTD |
PMID:18385449 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Retn |
resistin |
multiple interactions |
EXP |
N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased expression of RETN mRNA] |
CTD |
PMID:32298659 |
|
NCBI chr12:1,710,881...1,712,621
Ensembl chr12:1,710,881...1,712,620
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
increases import |
ISO |
SLC22A1 results in increased import of N(1)-methylnicotinamide |
CTD |
PMID:9260930 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Slc22a16 |
solute carrier family 22 member 16 |
multiple interactions |
ISO |
N(1)-methylnicotinamide inhibits the reaction [SLC22A16 protein results in increased uptake of Tetraethylammonium] |
CTD |
PMID:15963465 |
|
NCBI chr20:43,972,808...44,068,447
Ensembl chr20:43,972,836...44,065,019
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
increases import |
ISO |
SLC22A2 results in increased import of N(1)-methylnicotinamide |
CTD |
PMID:9260930 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
multiple interactions |
ISO |
N(1)-methylnicotinamide inhibits the reaction [SLC22A3 protein results in increased uptake of Tetraethylammonium] |
CTD |
PMID:10966924 |
|
NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
ISO |
3-aminobenzamide promotes the reaction [T0901317 results in increased expression of ABCA1 mRNA] 3-aminobenzamide promotes the reaction [Alitretinoin promotes the reaction [T0901317 results in increased expression of ABCA1 mRNA]]; 3-aminobenzamide promotes the reaction [Alitretinoin results in increased expression of ABCA1 mRNA]; 3-aminobenzamide promotes the reaction [T0901317 results in increased expression of ABCA1 mRNA] |
CTD |
PMID:27026705 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression |
EXP ISO |
3-aminobenzamide results in increased expression of ADIPOQ mRNA |
CTD |
PMID:18815186 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adipor1 |
adiponectin receptor 1 |
increases expression |
ISO EXP |
3-aminobenzamide results in increased expression of ADIPOR1 mRNA |
CTD |
PMID:18815186 |
|
NCBI chr13:45,859,461...45,879,248
Ensembl chr13:45,859,533...45,879,241
|
|
G |
Adipor2 |
adiponectin receptor 2 |
increases expression |
EXP ISO |
3-aminobenzamide results in increased expression of ADIPOR2 mRNA |
CTD |
PMID:18815186 |
|
NCBI chr 4:152,524,604...152,588,848
Ensembl chr 4:152,524,623...152,559,355
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions |
ISO |
3-aminobenzamide inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased activity of ATM protein] |
CTD |
PMID:22226932 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
increases expression |
ISO |
3-aminobenzamide results in increased expression of BGLAP mRNA |
CTD |
PMID:15670817 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP ISO |
3-aminobenzamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]; 3-aminobenzamide inhibits the reaction [SFRP1 protein promotes the reaction [Doxorubicin results in increased cleavage of CASP3 protein]] 3-aminobenzamide inhibits the reaction [[oxyhyponitrite results in increased abundance of nitroxyl] which results in increased activity of CASP3 protein] |
CTD |
PMID:11744336 PMID:16505238 PMID:30377735 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
3-aminobenzamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP9 protein] |
CTD |
PMID:16505238 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
3-aminobenzamide results in decreased expression of CCND1 mRNA |
CTD |
PMID:15670817 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
EXP |
3-aminobenzamide results in increased expression of CD36 mRNA |
CTD |
PMID:18815186 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
3-aminobenzamide results in increased expression of CDKN1A mRNA |
CTD |
PMID:15670817 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression |
ISO |
3-aminobenzamide results in decreased expression of CTNNB1 mRNA |
CTD |
PMID:15670817 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
3-aminobenzamide inhibits the reaction [Bleomycin results in increased secretion of CXCL2 protein] |
CTD |
PMID:26600069 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
3-aminobenzamide promotes the reaction [RB1 protein binds to E2F1 protein] |
CTD |
PMID:15670817 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
Ep300 |
E1A binding protein p300 |
multiple interactions |
EXP |
3-aminobenzamide inhibits the reaction [Streptozocin results in increased expression of EP300 mRNA] |
CTD |
PMID:22228707 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Ercc1 |
ERCC excision repair 1, endonuclease non-catalytic subunit |
multiple interactions decreases expression |
ISO EXP |
3-aminobenzamide inhibits the reaction [Glucose results in increased expression of ERCC1 mRNA]; 3-aminobenzamide inhibits the reaction [Glucose results in increased expression of ERCC1 protein] 3-aminobenzamide inhibits the reaction [Streptozocin results in increased expression of ERCC1 mRNA] 3-aminobenzamide results in decreased expression of ERCC1 mRNA; 3-aminobenzamide results in decreased expression of ERCC1 protein |
CTD |
PMID:22228707 |
|
NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963
|
|
G |
Ercc4 |
ERCC excision repair 4, endonuclease catalytic subunit |
multiple interactions decreases expression |
ISO EXP |
3-aminobenzamide inhibits the reaction [Glucose results in increased expression of ERCC4 mRNA]; 3-aminobenzamide inhibits the reaction [Glucose results in increased expression of ERCC4 protein] 3-aminobenzamide inhibits the reaction [Streptozocin results in increased expression of ERCC4 mRNA] 3-aminobenzamide results in decreased expression of ERCC4 mRNA; 3-aminobenzamide results in decreased expression of ERCC4 protein |
CTD |
PMID:22228707 |
|
NCBI chr10:2,416,259...2,448,364
Ensembl chr10:2,419,038...2,448,369
|
|
G |
Ercc6 |
ERCC excision repair 6, chromatin remodeling factor |
multiple interactions affects response to substance |
ISO |
3-aminobenzamide inhibits the reaction [ERCC6 gene mutant form results in increased abundance of Superoxides] ERCC6 gene mutant form affects the susceptibility to 3-aminobenzamide |
CTD |
PMID:25440059 |
|
NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions decreases expression |
ISO EXP |
3-aminobenzamide inhibits the reaction [Glucose results in increased expression of FN1 mRNA] 3-aminobenzamide inhibits the reaction [Streptozocin results in increased expression of FN1 mRNA] 3-aminobenzamide results in decreased expression of FN1 protein |
CTD |
PMID:22228707 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
multiple interactions |
ISO |
3-aminobenzamide inhibits the reaction [hydroquinone results in increased expression of HRAS protein] |
CTD |
PMID:26047893 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
decreases expression |
ISO |
3-aminobenzamide results in decreased expression of ID2 mRNA |
CTD |
PMID:15670817 |
|
NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
3-aminobenzamide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B mRNA] |
CTD |
PMID:19962977 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
3-aminobenzamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]]; 3-aminobenzamide inhibits the reaction [Glucose results in increased expression of INS mRNA]; 3-aminobenzamide inhibits the reaction [Glucose results in increased expression of INS protein] |
CTD |
PMID:16505238 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
ISO |
3-aminobenzamide results in decreased expression of JUN mRNA |
CTD |
PMID:15670817 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Lep |
leptin |
increases expression |
EXP |
3-aminobenzamide results in increased expression of LEP mRNA |
CTD |
PMID:18815186 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lpl |
lipoprotein lipase |
increases expression |
EXP |
3-aminobenzamide results in increased expression of LPL mRNA |
CTD |
PMID:18815186 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Mafa |
MAF bZIP transcription factor A |
multiple interactions |
ISO EXP |
3-aminobenzamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]] 3-aminobenzamide inhibits the reaction [Glucose results in decreased expression of MAFA mRNA]; 3-aminobenzamide inhibits the reaction [Glucose results in decreased expression of MAFA protein] |
CTD |
PMID:16505238 |
|
NCBI chr 7:107,432,292...107,435,084
Ensembl chr 7:107,433,605...107,434,690
|
|
G |
Mir126a |
microRNA 126a |
decreases expression multiple interactions |
ISO |
3-aminobenzamide results in decreased expression of MIR126 mRNA 3-aminobenzamide inhibits the reaction [Asbestos, Crocidolite results in increased expression of MIR126 mRNA]; [Decitabine co-treated with 3-aminobenzamide] inhibits the reaction [Asbestos, Crocidolite results in increased expression of MIR126 mRNA] |
CTD |
PMID:32006662 |
|
NCBI chr 3:9,415,063...9,415,180
Ensembl chr 3:9,415,063...9,415,180
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
3-aminobenzamide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of MPO protein] |
CTD |
PMID:19962977 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
ISO |
3-aminobenzamide results in decreased expression of MYC mRNA |
CTD |
PMID:15670817 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
3-aminobenzamide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NFKBIA mRNA] |
CTD |
PMID:19962977 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
decreases ADP-ribosylation |
ISO |
3-aminobenzamide results in decreased ADP-ribosylation of NR1H3 protein |
CTD |
PMID:27026705 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions decreases activity |
ISO EXP |
3-aminobenzamide inhibits the reaction [Asbestos, Amosite results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [Asbestos, Crocidolite results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [Benzoyl Peroxide results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [Capsaicin results in increased ADP-ribosylation of PARP1 protein modified form]; 3-aminobenzamide inhibits the reaction [Hydrogen Peroxide results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [hydroquinone results in increased expression of PARP1 protein]; 3-aminobenzamide inhibits the reaction [Lithocholic Acid analog results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [mezerein results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [PARP1 protein results in increased susceptibility to [Potassium Dichromate co-treated with nickel sulfate]]; 3-aminobenzamide inhibits the reaction [Smoke analog results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [sodium arsenite results in decreased expression of PARP1 protein]; 3-aminobenzamide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of PARP1 protein]; 3-aminobenzamide promotes the reaction [Capsaicin results in increased cleavage of and results in increased activity of PARP1 protein]; 3-aminobenzamide promotes the reaction [Capsaicin results in increased expression of PARP1 protein]; [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]; [3-aminobenzamide results in decreased activity of PARP1 protein] which results in increased susceptibility to Cisplatin 3-aminobenzamide inhibits the reaction [[sodium arsenite co-treated with lead acetate co-treated with Cadmium Chloride] results in increased cleavage of PARP1 protein]; 3-aminobenzamide inhibits the reaction [sodium arsenite results in increased cleavage of PARP1 protein] 3-aminobenzamide inhibits the reaction [PARP1 protein results in increased susceptibility to Acetaminophen] |
CTD |
PMID:2120135 PMID:2126186 PMID:11217149 PMID:15075382 PMID:15601672 PMID:15670817 PMID:17669606 PMID:18815186 PMID:19056730 PMID:20493934 PMID:21370912 PMID:21399878 PMID:21543585 PMID:22226932 PMID:26047893 PMID:27026705 PMID:27233451 PMID:28283887 PMID:36958258 More...
|
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Parp2 |
poly (ADP-ribose) polymerase 2 |
affects binding |
ISO |
PARP2 protein binds to 3-aminobenzamide |
CTD |
PMID:20092359 |
|
NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338
|
|
G |
Pcna |
proliferating cell nuclear antigen |
increases expression |
EXP |
3-aminobenzamide results in increased expression of PCNA protein |
CTD |
PMID:11049868 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pdx1 |
pancreatic and duodenal homeobox 1 |
multiple interactions |
EXP |
3-aminobenzamide inhibits the reaction [Palmitic Acid results in decreased expression of PDX1 protein] |
CTD |
PMID:19513971 |
|
NCBI chr12:7,757,865...7,763,064
Ensembl chr12:7,757,865...7,763,064
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases activity multiple interactions decreases ADP-ribosylation |
EXP |
3-aminobenzamide results in increased activity of PPARG protein 3-aminobenzamide inhibits the reaction [NAD results in decreased activity of PPARG protein] 3-aminobenzamide results in decreased ADP-ribosylation of PPARG protein |
CTD |
PMID:18815186 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Prkdc |
protein kinase, DNA-activated, catalytic subunit |
multiple interactions |
ISO |
3-aminobenzamide inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased activity of PRKDC protein] |
CTD |
PMID:22226932 |
|
NCBI chr11:85,040,790...85,258,357
Ensembl chr11:85,040,792...85,257,952
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
ISO |
3-aminobenzamide promotes the reaction [RB1 protein binds to E2F1 protein]; 3-aminobenzamide results in decreased phosphorylation of and results in increased activity of RB1 protein |
CTD |
PMID:15670817 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
3-aminobenzamide inhibits the reaction [Methylnitrosourea results in decreased expression of RELA protein modified form] |
CTD |
PMID:17137578 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sfrp1 |
secreted frizzled-related protein 1 |
multiple interactions |
EXP |
3-aminobenzamide inhibits the reaction [SFRP1 protein promotes the reaction [Doxorubicin results in increased cleavage of CASP3 protein]] |
CTD |
PMID:30377735 |
|
NCBI chr16:68,575,763...68,614,180
Ensembl chr16:68,575,763...68,614,286
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases expression |
ISO |
3-aminobenzamide results in increased expression of SPP1 mRNA |
CTD |
PMID:15670817 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Stk11 |
serine/threonine kinase 11 |
multiple interactions |
ISO |
3-aminobenzamide inhibits the reaction [resveratrol results in increased phosphorylation of STK11 protein] |
CTD |
PMID:19620254 |
|
NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315
|
|
G |
Tert |
telomerase reverse transcriptase |
multiple interactions |
ISO |
3-aminobenzamide inhibits the reaction [TERT protein mutant form results in decreased susceptibility to temozolomide] |
CTD |
PMID:12488552 |
|
NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
3-aminobenzamide inhibits the reaction [Capsaicin results in increased expression of TP53 protein]; 3-aminobenzamide inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased activity of TP53 protein] |
CTD |
PMID:22226932 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[1,5-dihydroxyisoquinoline co-treated with Tretinoin] results in decreased expression of BCL2 protein |
CTD |
PMID:10713328 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Edn1 |
endothelin 1 |
decreases expression |
EXP |
1,5-dihydroxyisoquinoline results in decreased expression of EDN1 mRNA; 1,5-dihydroxyisoquinoline results in decreased expression of EDN1 protein |
CTD |
PMID:12824290 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Ednra |
endothelin receptor type A |
decreases expression |
EXP |
1,5-dihydroxyisoquinoline results in decreased expression of EDNRA mRNA |
CTD |
PMID:12824290 |
|
NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049
|
|
G |
Ednrb |
endothelin receptor type B |
decreases expression |
EXP |
1,5-dihydroxyisoquinoline results in decreased expression of EDNRB mRNA |
CTD |
PMID:12824290 |
|
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
ISO |
1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of and results in increased acetylation of HMGB1 protein]; 1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of HMGB1 protein] |
CTD |
PMID:25517228 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions decreases activity decreases expression |
EXP ISO |
1,5-dihydroxyisoquinoline inhibits the reaction [Vancomycin results in increased expression of PARP1 protein] 1,5-dihydroxyisoquinoline results in decreased activity of PARP1 protein 1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [PARP1 protein binds to SIRT1 protein]] 1,5-dihydroxyisoquinoline results in decreased expression of PARP1 protein |
CTD |
PMID:12824290 PMID:19833176 PMID:25517228 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [PARP1 protein binds to SIRT1 protein]]; 1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased activity of SIRT1 protein]; Niacinamide inhibits the reaction [1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased activity of SIRT1 protein]] |
CTD |
PMID:25517228 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
increases abundance multiple interactions |
ISO |
IDH2 protein mutant form results in increased abundance of N-methylnicotinamide Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of N-methylnicotinamide] |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
affects abundance |
ISO |
SLCO1A4 protein affects the abundance of N-methylnicotinamide |
CTD |
PMID:21561886 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
|
G |
Ercc6 |
ERCC excision repair 6, chromatin remodeling factor |
multiple interactions |
ISO |
nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Adenosine Triphosphate]; nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of NAD] |
CTD |
PMID:25440059 |
|
NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
|
|
G |
Nqo2 |
N-ribosyldihydronicotinamide:quinone dehydrogenase 2 |
multiple interactions increases oxidation |
ISO |
[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of 2,6-Dichloroindophenol; [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q1; [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2; [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]; Melatonin inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; Melatonin inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]; N-(2-(2-methoxy-6H-dipyrido(2,3-a-3,2-e)pyrrolizin-11-yl)ethyl)-2-furamide inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; N-(2-(2-methoxy-6H-dipyrido(2,3-a-3,2-e)pyrrolizin-11-yl)ethyl)-2-furamide inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]; resveratrol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; resveratrol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3] NQO2 protein results in increased oxidation of nicotinamide-beta-riboside; NQO2 protein results in increased oxidation of nicotinamide-beta-riboside metabolite |
CTD |
PMID:20399199 PMID:29281794 |
|
NCBI chr17:30,909,482...30,938,725
Ensembl chr17:30,909,187...30,938,320
|
|
|
G |
Abcc9 |
ATP binding cassette subfamily C member 9 |
increases activity |
ISO |
Nicorandil results in increased activity of ABCC9 protein |
CTD |
PMID:22622455 |
|
NCBI chr 4:175,531,854...175,655,849
Ensembl chr 4:175,532,547...175,655,356
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO |
Nicorandil inhibits the reaction [AGT protein modified form results in increased expression of XDH protein] |
CTD |
PMID:22622455 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
Nicorandil inhibits the reaction [Folic Acid results in decreased expression of ALB protein] |
CTD |
PMID:33404076 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP ISO |
Nicorandil inhibits the reaction [Doxorubicin results in increased expression of BAX protein] Nicorandil inhibits the reaction [Folic Acid results in increased expression of BAX protein] |
CTD |
PMID:31376360 PMID:33404076 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein] |
CTD |
PMID:31376360 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
Nicorandil inhibits the reaction [Folic Acid results in increased expression of CASP3 protein] |
CTD |
PMID:33404076 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of CAT protein] |
CTD |
PMID:31376360 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ctsd |
cathepsin D |
multiple interactions |
EXP |
[Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in decreased activity of CTSD protein]; [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of CTSD protein] |
CTD |
PMID:11829124 PMID:14499179 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Gal |
galanin and GMAP prepropeptide |
multiple interactions |
EXP |
[Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in decreased activity of GAL protein]; [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of GAL protein] |
CTD |
PMID:11829124 PMID:14499179 |
|
NCBI chr 1:200,650,439...200,655,302
Ensembl chr 1:200,650,439...200,654,959
|
|
G |
Gusb |
glucuronidase, beta |
multiple interactions |
EXP |
[Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of GUSB protein] |
CTD |
PMID:11829124 PMID:14499179 |
|
NCBI chr12:26,701,188...26,714,718
Ensembl chr12:26,697,951...26,726,905
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
EXP |
Nicorandil inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 protein] |
CTD |
PMID:31376360 |
|
NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
|
|
G |
Hmox1 |
heme oxygenase 1 |
decreases expression |
EXP |
Nicorandil results in decreased expression of HMOX1 protein |
CTD |
PMID:22622455 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
Nicorandil inhibits the reaction [Doxorubicin results in increased expression of IL1B protein] |
CTD |
PMID:31376360 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Nicorandil inhibits the reaction [Folic Acid results in increased expression of IL6 protein] |
CTD |
PMID:33404076 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Nicorandil inhibits the reaction [Doxorubicin results in increased expression of MPO protein] |
CTD |
PMID:31376360 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of NFE2L2 protein] |
CTD |
PMID:31376360 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
Nicorandil inhibits the reaction [Doxorubicin results in increased expression of NFKB1 protein] |
CTD |
PMID:31376360 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Nicorandil inhibits the reaction [Folic Acid results in increased expression of NOS2 protein] |
CTD |
PMID:33404076 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
ISO |
Nicorandil inhibits the reaction [Folic Acid results in decreased expression of NOS3 protein] |
CTD |
PMID:33404076 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression |
EXP |
Nicorandil results in increased expression of SOD2 protein |
CTD |
PMID:22622455 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
EXP |
Nicorandil inhibits the reaction [Doxorubicin results in increased expression of TLR4 protein] |
CTD |
PMID:31376360 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
Nicorandil inhibits the reaction [Doxorubicin results in increased expression of TNF protein] Nicorandil inhibits the reaction [Folic Acid results in increased expression of TNF protein] |
CTD |
PMID:31376360 PMID:33404076 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions decreases expression |
ISO EXP |
Nicorandil inhibits the reaction [AGT protein modified form results in increased expression of XDH protein] Nicorandil results in decreased expression of XDH protein |
CTD |
PMID:22622455 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
IEP |
nicotinamide inhibits the reaction [5/6 nephrectomy increases the expression of Abca1 protein in kidney] |
RGD |
PMID:19878707 |
RGD:2326081 |
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions decreases phosphorylation |
ISO EXP |
Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of ACACA protein] [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of ACACA mRNA] Niacinamide results in decreased phosphorylation of ACACA protein |
CTD |
PMID:18482975 PMID:19071085 PMID:21212096 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
ISO |
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of ACE mRNA]; [Streptozocin co-treated with Niacinamide] results in increased expression of ACE mRNA; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of ACE mRNA] |
CTD |
PMID:37120126 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
multiple interactions |
ISO |
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of ACE2 mRNA]; [Streptozocin co-treated with Niacinamide] results in decreased expression of ACE2 mRNA; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of ACE2 mRNA] |
CTD |
PMID:37120126 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression |
EXP |
Niacinamide results in increased expression of ACTA2 mRNA; Niacinamide results in increased expression of ACTA2 protein |
CTD |
PMID:38555046 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases secretion multiple interactions |
ISO EXP |
Niacinamide results in increased secretion of ADIPOQ protein [Alloxan co-treated with Niacinamide] affects the expression of ADIPOQ protein; [Streptozocin co-treated with Niacinamide] results in decreased expression of ADIPOQ protein; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of ADIPOQ protein] |
CTD |
PMID:17452443 PMID:21439372 PMID:26429928 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Ago2 |
argonaute RISC catalytic component 2 |
multiple interactions |
ISO |
Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AGO2 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AGO2 protein] |
CTD |
PMID:24792773 |
|
NCBI chr 7:105,018,202...105,105,118
Ensembl chr 7:105,029,120...105,104,974
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
multiple interactions |
EXP ISO |
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [resveratrol results in decreased expression of AGTR1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of AGTR1 mRNA 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of AGTR1A mRNA]; [Streptozocin co-treated with Niacinamide] results in increased expression of AGTR1A mRNA; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of AGTR1A mRNA] |
CTD |
PMID:18420994 PMID:37120126 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
[Streptozocin co-treated with Niacinamide] results in decreased phosphorylation of AKT1 protein; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased phosphorylation of AKT1 protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:37566541 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
multiple interactions |
ISO |
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 protein] |
CTD |
PMID:25478867 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
EXP ISO |
Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of BAX protein] [Berberine co-treated with Niacinamide] results in increased expression of BAX protein [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX protein] Niacinamide results in increased expression of BAX mRNA; Niacinamide results in increased expression of BAX protein |
CTD |
PMID:16168987 PMID:16998810 PMID:25478867 PMID:26712469 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
multiple interactions increases expression |
ISO |
[Berberine co-treated with Niacinamide] results in increased expression of BBC3 mRNA Niacinamide results in increased expression of BBC3 mRNA |
CTD |
PMID:26712469 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein] [Berberine co-treated with Niacinamide] results in decreased expression of BCL2 protein; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein] |
CTD |
PMID:25472572 PMID:25478867 PMID:26712469 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
multiple interactions increases expression |
ISO |
[Berberine co-treated with Niacinamide] results in increased expression of BCL2L11 mRNA; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased expression of BCL2L11 protein] Niacinamide results in increased expression of BCL2L11 mRNA |
CTD |
PMID:25472572 PMID:26712469 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bmi1 |
BMI1 proto-oncogene, polycomb ring finger |
multiple interactions |
ISO |
Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BMI1 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BMI1 protein] |
CTD |
PMID:24792773 |
|
NCBI chr17:81,332,175...81,341,625
Ensembl chr17:81,332,214...81,388,690
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage |
EXP ISO |
Niacinamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein] Niacinamide results in increased cleavage of CASP3 protein [Berberine co-treated with Niacinamide] results in increased cleavage of CASP3 protein; resveratrol inhibits the reaction [Niacinamide results in increased cleavage of CASP3 protein] [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP3 protein]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP3 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 protein]; Niacinamide promotes the reaction [Antimycin A results in increased cleavage of CASP3 protein]; Niacinamide promotes the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein] |
CTD |
PMID:16505238 PMID:24040102 PMID:24962570 PMID:25478867 PMID:26712469 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP ISO |
Niacinamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP9 protein] [Berberine co-treated with Niacinamide] results in increased cleavage of CASP9 protein [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP9 protein]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP9 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 protein] |
CTD |
PMID:16505238 PMID:25478867 PMID:26712469 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein; [Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein; [Streptozocin co-treated with Niacinamide] results in decreased expression of CAT protein; coumarin inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; Diosmin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of CAT protein]; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Pioglitazone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of CAT protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Saponins inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; thymoquinone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein] 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; [Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein] |
CTD |
PMID:20307516 PMID:21382363 PMID:21439372 PMID:21630391 PMID:22056647 PMID:23677724 PMID:29247773 PMID:37120126 PMID:37566541 More...
|
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
Niacinamide results in decreased expression of CCL2 protein |
CTD |
PMID:14627904 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
increases expression |
ISO |
Niacinamide results in increased expression of CCL20 mRNA |
CTD |
PMID:22385246 |
|
NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
|
|
G |
Cd36 |
CD36 molecule |
decreases expression |
EXP |
nicotinamide decreases expression of Cd36 protein in kidney |
RGD |
PMID:19878707 |
RGD:2326081 |
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cd38 |
CD38 molecule |
multiple interactions |
ISO |
CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]] |
CTD |
PMID:20200208 |
|
NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986
|
|
G |
Cd40 |
CD40 molecule |
multiple interactions |
ISO |
Niacinamide promotes the reaction [TNF protein results in increased expression of CD40 mRNA] |
CTD |
PMID:22717288 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression decreases expression |
ISO EXP |
Niacinamide inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CDKN1A protein] Niacinamide results in increased expression of CDKN1A protein Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]] [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A protein] Niacinamide results in decreased expression of CDKN1A protein |
CTD |
PMID:12782109 PMID:22561310 PMID:25478867 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression multiple interactions |
EXP |
Niacinamide results in increased expression of CDKN1B protein Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]] |
CTD |
PMID:22561310 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions |
ISO |
Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of CDKN2A promoter] |
CTD |
PMID:24792773 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
increases activity multiple interactions |
ISO |
Niacinamide results in increased activity of CHUK protein resveratrol inhibits the reaction [Niacinamide results in increased activity of CHUK protein] |
CTD |
PMID:24962570 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression multiple interactions |
ISO EXP |
Niacinamide results in decreased expression of COL1A1 mRNA Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]] |
CTD |
PMID:16813520 PMID:25707573 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
multiple interactions |
ISO |
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A2 mRNA]] |
CTD |
PMID:25707573 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
decreases expression |
EXP |
Nicotinamide decreases expression of Cpt1a protein in kidney of 5/6 nephrectomized rats |
RGD |
PMID:19878707 |
RGD:2326081 |
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions increases expression |
EXP |
Clofibrate inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA]; GW 6471 inhibits the reaction [Resveratrol inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA]]; Resveratrol inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA] |
CTD |
PMID:23422569 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
ISO |
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NOX2 mRNA]; [Streptozocin co-treated with Niacinamide] results in increased expression of NOX2 mRNA; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NOX2 mRNA] |
CTD |
PMID:37120126 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
Niacinamide inhibits the reaction [Letrozole results in increased expression of CYP17A1 mRNA] |
CTD |
PMID:32298659 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
[Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA] |
CTD |
PMID:27919644 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
[Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA] |
CTD |
PMID:27919644 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Defb5 |
defensin beta 5 |
multiple interactions |
ISO |
[Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DEFB4A mRNA |
CTD |
PMID:24894820 |
|
NCBI chr16:70,612,985...70,615,389
Ensembl chr16:70,613,146...70,615,467
|
|
G |
Dicer1 |
dicer 1 ribonuclease III |
multiple interactions |
ISO |
Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DICER1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DICER1 protein] |
CTD |
PMID:24792773 |
|
NCBI chr 6:123,627,529...123,692,278
Ensembl chr 6:123,631,250...123,693,965
|
|
G |
Dlg1 |
discs large MAGUK scaffold protein 1 |
multiple interactions |
ISO |
[Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DLG1 mRNA; Niacinamide inhibits the reaction [geranylgeranylacetone results in increased expression of DLG1 mRNA] |
CTD |
PMID:21232033 |
|
NCBI chr11:68,911,883...69,103,230
Ensembl chr11:68,911,883...69,102,689
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions |
ISO |
Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 protein] |
CTD |
PMID:24792773 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
increases phosphorylation multiple interactions |
ISO |
Niacinamide results in increased phosphorylation of EIF4EBP1 protein [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of EIF4EBP1 protein; Niacinamide inhibits the reaction [Resveratrol results in decreased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:19928762 PMID:20169165 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Ercc6 |
ERCC excision repair 6, chromatin remodeling factor |
increases abundance multiple interactions |
ISO |
ERCC6 gene mutant form results in increased abundance of Niacinamide ERCC6 gene mutant form promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in decreased abundance of Niacinamide] |
CTD |
PMID:25440059 |
|
NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
|
|
G |
F3 |
coagulation factor III, tissue factor |
decreases expression |
ISO |
Niacinamide results in decreased expression of F3 protein |
CTD |
PMID:14627904 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
multiple interactions |
EXP |
nicotinamide inhibits the reaction [5/6 nephrectomy decreases the expression of Fabp1 protein in kidney] |
RGD |
PMID:19878707 |
RGD:2326081 |
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]; Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]] |
CTD |
PMID:20200208 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of FOS protein] |
CTD |
PMID:16168987 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO EXP |
Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of G6PC1 mRNA]; Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of IGFBP1 mRNA] [Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO1 protein; Niacinamide results in increased expression of and results in increased acetylation of FOXO1 protein Niacinamide inhibits the reaction [Dexamethasone results in decreased acetylation of FOXO1 protein]; Niacinamide inhibits the reaction [FOXO1 protein binds to SIRT1 protein] |
CTD |
PMID:16917544 PMID:20181797 PMID:26712469 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO3 protein; Niacinamide inhibits the reaction [icariin inhibits the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased acetylation of and results in increased expression of FOXO3 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of FOXO3 protein]; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased acetylation of FOXO3 protein]; Niacinamide results in increased expression of and results in increased acetylation of FOXO3 protein |
CTD |
PMID:23022493 PMID:25472572 PMID:26712469 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Fth1 |
ferritin heavy chain 1 |
increases expression |
ISO |
Niacinamide results in increased expression of FTH1 mRNA; Niacinamide results in increased expression of FTH1 protein |
CTD |
PMID:23738040 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of G6PC1 mRNA] |
CTD |
PMID:16917544 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions |
EXP |
[Streptozocin co-treated with Niacinamide] affects the activity of G6PD protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of G6PD protein] |
CTD |
PMID:19059388 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gcg |
glucagon |
multiple interactions |
EXP |
[Streptozocin co-treated with Niacinamide] results in decreased expression of GCG mRNA; Sitagliptin Phosphate inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCG mRNA] |
CTD |
PMID:23466488 |
|
NCBI chr 3:47,113,914...47,122,958
Ensembl chr 3:47,113,914...47,122,929
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
EXP |
[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA; [Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein] |
CTD |
PMID:21439372 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Glb1 |
galactosidase, beta 1 |
multiple interactions increases expression |
EXP |
Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]] Niacinamide results in increased expression of GLB1 protein |
CTD |
PMID:22561310 |
|
NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127
|
|
G |
Glo1 |
glyoxalase 1 |
multiple interactions |
EXP |
[Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein] |
CTD |
PMID:21439372 |
|
NCBI chr20:8,663,617...8,681,661
Ensembl chr20:8,662,801...8,681,649
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
[Resveratrol co-treated with Niacinamide] inhibits the reaction [[Aflatoxin B1 co-treated with Ethanol] results in increased expression of GPT protein] |
CTD |
PMID:32894639 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
[Niacinamide co-treated with Resveratrol] inhibits the reaction [[Ethanol co-treated with Aflatoxin B1] results in decreased expression of GSR protein]; [Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein; [Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein] |
CTD |
PMID:20307516 PMID:21439372 PMID:32894639 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
multiple interactions |
EXP |
[Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA] |
CTD |
PMID:21439372 |
|
NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
EXP |
[Niacinamide co-treated with Resveratrol] inhibits the reaction [[Ethanol co-treated with Aflatoxin B1] results in increased expression of GSTP1 protein] |
CTD |
PMID:32894639 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gys2 |
glycogen synthase 2 |
multiple interactions |
EXP |
[Streptozocin co-treated with Niacinamide] affects the activity of GYS2 protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of GYS2 protein] |
CTD |
PMID:19059388 |
|
NCBI chr 4:175,365,054...175,406,228
Ensembl chr 4:175,365,054...175,406,228
|
|
G |
Hba-a2 |
hemoglobin alpha, adult chain 2 |
multiple interactions |
EXP |
[Streptozocin co-treated with Niacinamide] results in increased glycosylation of HBA1 protein; coumarin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased glycosylation of HBA1 protein] |
CTD |
PMID:19647726 |
|
NCBI chr10:15,323,830...15,324,677
Ensembl chr10:15,307,815...15,338,392
|
|
G |
Hdac1 |
histone deacetylase 1 |
multiple interactions |
ISO |
Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of HDAC1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of HDAC1 protein] |
CTD |
PMID:24792773 |
|
NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions decreases expression |
EXP |
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of HMGCR mRNA]; [Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein] Nicotinamide decreases expression of Hmgcr protein in kidney of 5/6 nephrectomized rats |
CTD RGD |
PMID:20696151 PMID:21212096 PMID:19878707 |
RGD:2326081 |
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
[Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein] |
CTD |
PMID:21439372 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]] |
CTD |
PMID:24145604 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Niacinamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
multiple interactions |
ISO |
Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of IGFBP1 mRNA] |
CTD |
PMID:16917544 |
|
NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 mRNA]; 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 protein]; [Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 mRNA; [Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 mRNA]; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 protein] |
CTD |
PMID:37120126 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
EXP |
[Streptozocin co-treated with Niacinamide co-treated with ENV-2 compound] results in decreased expression of IL18 mRNA |
CTD |
PMID:28322830 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases expression increases expression |
EXP ISO |
[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein; [Streptozocin co-treated with Niacinamide co-treated with ENV-2 compound] results in decreased expression of IL1B mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein] Niacinamide results in decreased expression of IL1B mRNA Niacinamide results in increased expression of IL1B mRNA |
CTD |
PMID:20307516 PMID:21439372 PMID:22385246 PMID:28322830 PMID:29594315 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
[Niacinamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il6 |
interleukin 6 |
decreases expression multiple interactions |
ISO EXP |
Niacinamide results in decreased expression of IL6 protein [Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein; [Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein] |
CTD |
PMID:12727023 PMID:20307516 PMID:21439372 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
[Niacinamide co-treated with Streptozocin] results in decreased expression of INS1 protein; [Streptozocin co-treated with Niacinamide] results in decreased expression of INS1 protein; [Streptozocin co-treated with Niacinamide] results in decreased secretion of INS1 protein; [Streptozocin co-treated with Niacinamide] results in increased expression of INS1 protein; coumarin inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased expression of INS1 protein]; coumarin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of INS1 protein]; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of INS1 protein]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS1 protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of INS1 protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of INS1 protein]; thymoquinone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of INS1 protein]; thymoquinone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased secretion of INS1 protein] |
CTD |
PMID:16366736 PMID:19647726 PMID:21382363 PMID:21630391 PMID:25999625 PMID:37566541 More...
|
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
Niacinamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS mRNA]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS protein] |
CTD |
PMID:16505238 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Insr |
insulin receptor |
multiple interactions |
EXP |
[Streptozocin co-treated with Niacinamide] results in decreased expression of INSR protein; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of INSR protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of INSR protein] |
CTD |
PMID:37566541 |
|
NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883
|
|
G |
Irs2 |
insulin receptor substrate 2 |
multiple interactions |
EXP |
[Streptozocin co-treated with Niacinamide] results in decreased expression of IRS2 protein; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IRS2 protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IRS2 protein] |
CTD |
PMID:37566541 |
|
NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of JUN protein]; Niacinamide inhibits the reaction [Methylnitrosourea results in increased phosphorylation of JUN protein] |
CTD |
PMID:16168987 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
EXP ISO |
[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein] 2,5-dihydroxybenzoic acid promotes the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of KEAP1 mRNA]; [Streptozocin co-treated with Niacinamide] results in decreased expression of KEAP1 mRNA; Metformin promotes the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of KEAP1 mRNA]; Niacinamide inhibits the reaction [Acetaminophen results in increased expression of KEAP1 protein] |
CTD |
PMID:21439372 PMID:33949241 PMID:37120126 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Klf4 |
KLF transcription factor 4 |
multiple interactions |
EXP |
[Streptozocin co-treated with Niacinamide] promotes the reaction [Dronabinol results in increased expression of KLF4 mRNA] |
CTD |
PMID:31081965 |
|
NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
|
|
G |
Lcat |
lecithin cholesterol acyltransferase |
multiple interactions |
EXP |
[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein] |
CTD |
PMID:20696151 |
|
NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
EXP |
Niacinamide inhibits the reaction [Letrozole results in increased secretion of LHB protein] |
CTD |
PMID:32298659 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
EXP |
[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein] |
CTD |
PMID:20696151 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Mafa |
MAF bZIP transcription factor A |
multiple interactions |
ISO |
Niacinamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]] |
CTD |
PMID:16505238 |
|
NCBI chr 7:107,432,292...107,435,084
Ensembl chr 7:107,433,605...107,434,690
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
Niacinamide inhibits the reaction [[TNF protein co-treated with resveratrol] results in increased expression of MAP1LC3B protein alternative form] |
CTD |
PMID:24145604 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
Niacinamide inhibits the reaction [Methylnitrosourea results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:16168987 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases expression |
ISO |
Niacinamide results in increased expression of MDM2 mRNA |
CTD |
PMID:16998810 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mir200a |
microRNA 200a |
multiple interactions |
ISO |
2,5-dihydroxybenzoic acid promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of MIR200A]; [Streptozocin co-treated with Niacinamide] results in increased expression of MIR200A; Metformin promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of MIR200A] |
CTD |
PMID:37120126 |
|
NCBI chr 5:166,648,494...166,648,582
|
|
G |
Mir3545 |
microRNA 3545 |
multiple interactions |
ISO |
Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene affects the expression of MIR203 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of MIR203 promoter] |
CTD |
PMID:24792773 |
|
NCBI chr 6:131,199,542...131,199,656
Ensembl chr 6:131,199,542...131,199,656
|
|
G |
Mlxipl |
MLX interacting protein-like |
multiple interactions |
EXP |
nicotinamide inhibits the reaction [5/6 nephrectomy increases the expression of Mlxipl protein in kidney] |
RGD |
PMID:19878707 |
RGD:2326081 |
NCBI chr12:21,541,608...21,577,120
Ensembl chr12:21,543,576...21,577,112
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression multiple interactions |
ISO |
Niacinamide results in increased expression of MMP9 protein Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of MMP9 protein]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of MMP9 protein] |
CTD |
PMID:24145604 PMID:24962570 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Msra |
methionine sulfoxide reductase A |
multiple interactions |
ISO |
Niacinamide inhibits the reaction [resveratrol results in increased expression of MSRA protein] |
CTD |
PMID:23022493 |
|
NCBI chr15:38,363,459...38,677,406
Ensembl chr15:38,351,445...38,676,585
|
|
G |
Mt-co1 |
mitochondrially encoded cytochrome c oxidase I |
increases expression |
ISO |
Niacinamide results in increased expression of COX1 mRNA; Niacinamide results in increased expression of COX1 protein |
CTD |
PMID:23738040 |
|
NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
increases phosphorylation multiple interactions |
ISO |
Niacinamide results in increased phosphorylation of MTOR protein Niacinamide inhibits the reaction [resveratrol results in decreased phosphorylation of MTOR protein] |
CTD |
PMID:19928762 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC protein]; Niacinamide inhibits the reaction [Butylhydroxybutylnitrosamine results in increased expression of and results in increased localization of MYC protein] |
CTD |
PMID:22028816 PMID:24792773 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nabp2 |
nucleic acid binding protein 2 |
decreases ubiquitination increases acetylation multiple interactions |
ISO |
Niacinamide results in decreased ubiquitination of NABP2 protein Niacinamide results in increased acetylation of NABP2 protein Niacinamide promotes the reaction [trichostatin A results in decreased ubiquitination of NABP2 protein]; Niacinamide promotes the reaction [trichostatin A results in increased acetylation of NABP2 protein]; trichostatin A promotes the reaction [Niacinamide results in decreased ubiquitination of NABP2 protein]; trichostatin A promotes the reaction [Niacinamide results in increased acetylation of NABP2 protein] |
CTD |
PMID:26170237 |
|
NCBI chr 7:830,949...836,551
Ensembl chr 7:830,949...838,027
|
|
G |
Nampt |
nicotinamide phosphoribosyltransferase |
decreases expression multiple interactions |
ISO EXP |
Niacinamide results in decreased expression of NAMPT protein Niacinamide inhibits the reaction [[Acetaminophen results in decreased expression of NAMPT protein] which results in decreased abundance of NAD]; Niacinamide inhibits the reaction [Acetaminophen results in decreased expression of NAMPT protein] Niacinamide inhibits the reaction [Letrozole results in increased expression of NAMPT mRNA] [Berberine co-treated with Niacinamide] results in decreased expression of NAMPT protein |
CTD |
PMID:26712469 PMID:32298659 PMID:33949241 |
|
NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
|
|
G |
Ncor1 |
nuclear receptor co-repressor 1 |
decreases expression multiple interactions |
ISO |
Niacinamide results in decreased expression of NCOR1 protein Niacinamide affects the reaction [PPARG protein binds to NCOR1 protein] |
CTD |
PMID:22539994 |
|
NCBI chr10:46,999,536...47,142,294
Ensembl chr10:46,999,536...47,141,032
|
|
G |
Ndufa1 |
NADH:ubiquinone oxidoreductase subunit A1 |
multiple interactions |
EXP |
Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA1 mRNA] |
CTD |
PMID:23891692 |
|
NCBI chr X:116,424,223...116,427,875
Ensembl chr X:116,424,223...116,428,633
|
|
G |
Ndufa13 |
NADH:ubiquinone oxidoreductase subunit A13 |
multiple interactions |
EXP |
Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA13 mRNA]; Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA13 protein] |
CTD |
PMID:23891692 |
|
NCBI chr16:19,526,633...19,533,567
Ensembl chr16:19,526,565...19,535,726
|
|
G |
Ndufa2 |
NADH:ubiquinone oxidoreductase subunit A2 |
multiple interactions |
EXP |
Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA2 mRNA] |
CTD |
PMID:23891692 |
|
NCBI chr18:28,355,774...28,357,863
Ensembl chr18:28,355,774...28,358,076
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP ISO |
[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA; [Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein] 2,5-dihydroxybenzoic acid promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NFE2L2 protein]; [Niacinamide co-treated with Acetaminophen] affects the localization of NFE2L2 protein; [Streptozocin co-treated with Niacinamide] results in increased expression of NFE2L2 protein; Metformin promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NFE2L2 protein]; Niacinamide inhibits the reaction [Acetaminophen results in decreased expression of NFE2L2 protein] |
CTD |
PMID:21439372 PMID:33949241 PMID:37120126 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
[Resveratrol co-treated with Niacinamide] inhibits the reaction [[Aflatoxin B1 co-treated with Ethanol] results in increased expression of NFKB1 mRNA] |
CTD |
PMID:32894639 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Niacinamide inhibits the reaction [resveratrol results in decreased expression of NOS2 mRNA]; Niacinamide inhibits the reaction [resveratrol results in decreased expression of NOS2 protein] |
CTD |
PMID:23735732 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nox4 |
NADPH oxidase 4 |
multiple interactions increases expression |
EXP |
GW 6471 inhibits the reaction [resveratrol inhibits the reaction [Niacinamide results in increased expression of NOX4 mRNA]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of NOX4 mRNA] |
CTD |
PMID:23422569 |
|
NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
2,5-dihydroxybenzoic acid promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NQO1 mRNA]; [Streptozocin co-treated with Niacinamide] results in increased expression of NQO1 mRNA; Metformin promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NQO1 mRNA] |
CTD |
PMID:37120126 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
ISO |
[Glycerol co-treated with Succinic Acid co-treated with Glucose-6-Phosphate co-treated with Pantothenic Acid co-treated with Niacinamide] results in increased expression of NR4A1 mRNA |
CTD |
PMID:20505214 |
|
NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Ogdh |
oxoglutarate dehydrogenase |
multiple interactions |
ISO |
Niacinamide inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased activity of OGDH protein] |
CTD |
PMID:18381761 |
|
NCBI chr14:81,150,021...81,217,479
Ensembl chr14:81,150,091...81,217,479
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases expression increases cleavage decreases activity |
EXP ISO |
Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in decreased expression of PARP1 protein]; Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in increased activity of PARP1 protein]; Niacinamide inhibits the reaction [Methylnitrosourea results in increased activity of PARP1 protein] Niacinamide results in increased expression of PARP1 mRNA; Niacinamide results in increased expression of PARP1 protein [Berberine co-treated with Niacinamide] results in increased cleavage of PARP1 protein; Niacinamide inhibits the reaction [sodium arsenite results in decreased expression of PARP1 protein] Niacinamide results in increased cleavage of PARP1 protein Niacinamide results in decreased activity of PARP1 protein |
CTD |
PMID:16168987 PMID:19288225 PMID:26712469 PMID:29143419 PMID:36958258 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
multiple interactions |
EXP |
Niacinamide inhibits the reaction [Dexamethasone results in increased expression of PDK4 protein] |
CTD |
PMID:20181797 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Pdp1 |
pyruvate dehydrogenase phosphatase catalytic subunit 1 |
multiple interactions |
EXP |
Niacinamide inhibits the reaction [Dexamethasone results in increased phosphorylation of PDP1 protein] |
CTD |
PMID:20181797 |
|
NCBI chr 5:25,446,843...25,455,107
Ensembl chr 5:25,446,272...25,455,217
|
|
G |
Pitx2 |
paired-like homeodomain 2 |
increases expression |
ISO |
Niacinamide results in increased expression of PITX2 mRNA; Niacinamide results in increased expression of PITX2 protein |
CTD |
PMID:29143419 |
|
NCBI chr 2:217,717,738...217,737,293
Ensembl chr 2:217,717,693...217,737,293
|
|
G |
Pmp22 |
peripheral myelin protein 22 |
multiple interactions |
ISO |
Niacinamide inhibits the reaction [Butylhydroxybutylnitrosamine results in decreased expression of and results in decreased localization of PMP22 protein] |
CTD |
PMID:22028816 |
|
NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases expression |
ISO EXP |
Niacinamide affects the reaction [PPARG protein binds to NCOR1 protein]; resveratrol inhibits the reaction [Niacinamide results in increased expression of PPARG protein] [Streptozocin co-treated with Niacinamide] results in decreased expression of PPARG protein; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of PPARG protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of PPARG protein] |
CTD |
PMID:22539994 PMID:37566541 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases acetylation multiple interactions |
ISO EXP |
Niacinamide results in increased acetylation of PPARGC1A protein [Niacinamide results in decreased activity of SIRT1 protein] which results in increased acetylation of PPARGC1A protein [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [SIRT1 protein results in increased expression of PPARGC1A mRNA] |
CTD |
PMID:19071085 PMID:23422569 PMID:23891692 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
ISO |
Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of PRKAA1 protein] |
CTD |
PMID:18482975 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkaa2 |
protein kinase AMP-activated catalytic subunit alpha 2 |
multiple interactions |
ISO |
Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of PRKAA2 protein] |
CTD |
PMID:18482975 |
|
NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
ISO |
Niacinamide results in increased expression of PTGS2 protein Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of PTGS2 protein] |
CTD |
PMID:24145604 PMID:24962570 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pygl |
glycogen phosphorylase L |
multiple interactions |
EXP |
[Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein] |
CTD |
PMID:19059388 |
|
NCBI chr 6:88,697,598...88,740,260
Ensembl chr 6:88,697,593...88,740,310
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP ISO |
[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein; [Streptozocin co-treated with Niacinamide] results in increased activity of RELA protein; [Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein]; Niacinamide inhibits the reaction [AICA ribonucleotide inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [Metformin inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [Salicylic Acid inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased activity of RELA protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein] Niacinamide results in increased acetylation of and results in increased phosphorylation of RELA protein; resveratrol inhibits the reaction [Niacinamide results in increased phosphorylation of and results in increased acetylation of RELA protein] 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased phosphorylation of RELA protein]; [Streptozocin co-treated with Niacinamide] results in increased phosphorylation of RELA protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased phosphorylation of RELA protein]; Niacinamide inhibits the reaction [Resveratrol results in decreased expression of RELA protein modified form]; Niacinamide promotes the reaction [TNF protein results in increased acetylation of RELA protein] |
CTD |
PMID:20307516 PMID:21439372 PMID:22717288 PMID:23406761 PMID:23735732 PMID:24962570 PMID:25108154 PMID:37120126 More...
|
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rps6 |
ribosomal protein S6 |
multiple interactions |
ISO |
[Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of RPS6 protein |
CTD |
PMID:20169165 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
decreases expression multiple interactions increases expression |
ISO EXP |
Niacinamide results in decreased expression of RUNX2 mRNA; Niacinamide results in decreased expression of RUNX2 protein resveratrol inhibits the reaction [Niacinamide results in decreased expression of RUNX2 protein] Niacinamide results in increased expression of RUNX2 mRNA |
CTD |
PMID:16813520 PMID:22539994 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Scaf1 |
SR-related CTD-associated factor 1 |
increases expression |
EXP |
nicotinamide increases expression of Scaf1 protein in kidney |
RGD |
PMID:19878707 |
RGD:2326081 |
NCBI chr 1:95,485,448...95,499,389
Ensembl chr 1:95,485,448...95,496,029
|
|
G |
Scap |
SREBF chaperone |
increases expression |
IEP |
nicotinamide increases expression of Scap protein in kidney of 5/6 nephrectomized rat |
RGD |
PMID:19878707 |
RGD:2326081 |
NCBI chr 8:110,306,026...110,360,677
Ensembl chr 8:110,306,031...110,360,666
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
decreases expression |
EXP |
nicotinamide inhibits the reaction [5/6 nephrectomy increases the expression of Scarb1 protein in kidney] |
RGD |
PMID:19878707 |
RGD:2326081 |
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Shc1 |
SHC adaptor protein 1 |
multiple interactions increases expression |
ISO |
Niacinamide promotes the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased expression of SHC1 protein] Niacinamide results in increased expression of SHC1 mRNA; Niacinamide results in increased expression of SHC1 protein |
CTD |
PMID:21778425 PMID:24557422 |
|
NCBI chr 2:174,837,937...174,849,538
Ensembl chr 2:174,837,930...174,849,536
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions decreases expression decreases activity |
ISO EXP |
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [SIRT1 protein results in increased expression of PPARGC1A mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DLG1 mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to resveratrol; Niacinamide inhibits the reaction [[SIRT1 protein binds to UCP2 promoter] which results in decreased expression of UCP2 mRNA] Niacinamide results in decreased expression of SIRT1 mRNA; Niacinamide results in decreased expression of SIRT1 protein [Niacinamide co-treated with Resveratrol] promotes the reaction [[Ethanol co-treated with Aflatoxin B1] results in increased expression of SIRT1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Cholesterol]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Glucose]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of ACACA mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of HMGCR mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Resveratrol results in decreased expression of AGTR1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to AICA ribonucleotide; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Fructose; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Metformin; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Resveratrol; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Salicylic Acid; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased acetylation of PPARGC1A protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of AGTR1 mRNA; [Resveratrol co-treated with Niacinamide] promotes the reaction [[Ethanol co-treated with Aflatoxin B1] results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in decreased expression of and results in decreased activity of SIRT1 protein]; Niacinamide inhibits the reaction [FOXO1 protein binds to SIRT1 protein]; Niacinamide inhibits the reaction [Resveratrol promotes the reaction [Pilocarpine results in increased expression of SIRT1 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 mRNA]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [SIRT1 protein results in decreased abundance of NAD] [Berberine co-treated with Niacinamide] results in decreased expression of SIRT1 protein; [Niacinamide results in decreased activity of SIRT1 protein] promotes the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DEFB4A mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of CXCL8 mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of EIF4EBP1 protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of RPS6 protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased susceptibility to Hydrogen Peroxide; Niacinamide inhibits the reaction [1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased activity of SIRT1 protein]]; Niacinamide inhibits the reaction [icariin inhibits the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of SIRT1 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [salvin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of SIRT1 protein]]; Niacinamide promotes the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of SIRT1 protein]; Niacinamide results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein] |
CTD |
PMID:16366736 PMID:17103016 PMID:18420994 PMID:18482975 PMID:18681908 PMID:19071085 PMID:19288225 PMID:19664641 PMID:19928762 PMID:20169165 PMID:20181797 PMID:21212096 PMID:21232033 PMID:21745208 PMID:21892612 PMID:22385246 PMID:22561310 PMID:22990594 PMID:23211629 PMID:23422569 PMID:23479127 PMID:23735732 PMID:23891692 PMID:24557422 PMID:24894820 PMID:25108154 PMID:25472572 PMID:25517228 PMID:26712469 PMID:28973641 PMID:32894639 PMID:34216621 PMID:38555046 More...
|
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Sirt2 |
sirtuin 2 |
decreases activity multiple interactions |
ISO |
Niacinamide results in decreased activity of SIRT2 protein [Berberine co-treated with Niacinamide] results in decreased expression of SIRT2 protein |
CTD |
PMID:17341628 PMID:26712469 |
|
NCBI chr 1:84,053,883...84,076,975
Ensembl chr 1:84,052,903...84,076,975
|
|
G |
Sirt3 |
sirtuin 3 |
multiple interactions |
ISO |
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT3 protein |
CTD |
PMID:26712469 |
|
NCBI chr 1:195,942,066...195,964,472
Ensembl chr 1:195,942,073...195,964,808
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
EXP |
[Streptozocin co-treated with Niacinamide] results in decreased expression of SLC2A4 protein; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of SLC2A4 protein]; Niacinamide inhibits the reaction [Letrozole results in decreased expression of SLC2A4 mRNA]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of SLC2A4 protein] |
CTD |
PMID:32298659 PMID:37566541 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
affects abundance |
ISO |
SLCO1A4 protein affects the abundance of Niacinamide |
CTD |
PMID:21561886 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Smad3 |
SMAD family member 3 |
increases phosphorylation increases expression |
EXP |
Niacinamide results in increased phosphorylation of SMAD3 protein Niacinamide results in increased expression of SMAD3 mRNA |
CTD |
PMID:38555046 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Smad7 |
SMAD family member 7 |
decreases expression |
EXP |
Niacinamide results in decreased expression of SMAD7 mRNA; Niacinamide results in decreased expression of SMAD7 protein |
CTD |
PMID:38555046 |
|
NCBI chr18:68,988,429...69,016,774
Ensembl chr18:68,988,429...69,016,765
|
|
G |
Snap23 |
synaptosome associated protein 23 |
multiple interactions |
EXP |
[Streptozocin co-treated with Niacinamide] results in decreased expression of SNAP23 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of SNAP23 mRNA] |
CTD |
PMID:25999625 |
|
NCBI chr 3:107,514,088...107,546,177
Ensembl chr 3:107,514,131...107,544,320
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP ISO |
[Streptozocin co-treated with Niacinamide] results in increased expression of SOD1 protein; Dronabinol promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of SOD1 protein] 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of SOD1 protein]; [Streptozocin co-treated with Niacinamide] results in decreased activity of SOD1 protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of SOD1 protein] |
CTD |
PMID:31081965 PMID:37120126 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP ISO |
Niacinamide inhibits the reaction [resveratrol results in increased expression of SOD2 mRNA] Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of SOD2 protein] |
CTD |
PMID:23891692 PMID:25472572 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
decreases expression multiple interactions |
ISO |
Niacinamide results in decreased expression of SOX9 protein 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline inhibits the reaction [Niacinamide results in decreased expression of SOX9 protein]; resveratrol inhibits the reaction [Niacinamide results in decreased expression of SOX9 protein] |
CTD |
PMID:24962570 |
|
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
Niacinamide inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein] |
CTD |
PMID:24238063 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
Niacinamide inhibits the reaction [platycodin D inhibits the reaction [Glucose results in increased expression of SREBF1 protein]] |
CTD |
PMID:23319015 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Stx4 |
syntaxin 4 |
multiple interactions |
EXP |
[Streptozocin co-treated with Niacinamide] results in decreased expression of STX4 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of STX4 mRNA] |
CTD |
PMID:25999625 |
|
NCBI chr 1:182,451,108...182,459,701
Ensembl chr 1:182,451,117...182,459,979
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions increases expression |
ISO EXP |
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 mRNA]; 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 protein]; [Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 mRNA]; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 protein] Niacinamide results in increased expression of TGFB1 mRNA; Niacinamide results in increased expression of TGFB1 protein |
CTD |
PMID:37120126 PMID:38555046 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
multiple interactions |
ISO |
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A2 mRNA]] |
CTD |
PMID:25707573 |
|
NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
EXP ISO |
[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein; [Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein] Niacinamide inhibits the reaction [[TNF protein co-treated with resveratrol] results in increased expression of MAP1LC3B protein alternative form]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of MMP9 protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]] 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF mRNA]; 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein]; [Streptozocin co-treated with Niacinamide] results in increased expression of TNF mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF mRNA]; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein]; Niacinamide promotes the reaction [TNF protein results in increased acetylation of RELA protein]; Niacinamide promotes the reaction [TNF protein results in increased expression of CD40 mRNA] Niacinamide results in increased expression of TNF mRNA |
CTD |
PMID:20307516 PMID:21439372 PMID:22385246 PMID:22717288 PMID:24145604 PMID:31081965 PMID:37120126 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
decreases expression |
ISO |
Niacinamide results in decreased expression of TNFRSF11B mRNA |
CTD |
PMID:16813520 |
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
decreases expression |
ISO |
Niacinamide results in decreased expression of TNFSF11 mRNA |
CTD |
PMID:16813520 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions decreases expression |
ISO |
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of TP53 protein; [Niacinamide results in decreased activity of SIRT1 protein] promotes the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein]; Niacinamide inhibits the reaction [tert-Butylhydroperoxide results in increased expression of TP53 protein]; Niacinamide results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein]; Niacinamide results in increased phosphorylation of and results in increased acetylation of TP53 protein [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 mRNA alternative form]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 mRNA alternative form]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 protein] Niacinamide results in decreased expression of TP53 protein |
CTD |
PMID:12782109 PMID:18482975 PMID:18681908 PMID:25478867 PMID:26712469 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tyr |
tyrosinase |
increases expression |
ISO |
Niacinamide results in increased expression of TYR mRNA; Niacinamide results in increased expression of TYR protein |
CTD |
PMID:23738040 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions |
ISO |
Niacinamide inhibits the reaction [[SIRT1 protein binds to UCP2 promoter] which results in decreased expression of UCP2 mRNA] |
CTD |
PMID:16366736 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Vamp2 |
vesicle-associated membrane protein 2 |
multiple interactions |
EXP |
[Streptozocin co-treated with Niacinamide] results in decreased expression of VAMP2 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of VAMP2 mRNA] |
CTD |
PMID:25999625 |
|
NCBI chr10:53,793,581...53,797,815
Ensembl chr10:53,793,923...53,797,809
|
|
|
G |
H2ax |
H2A.X variant histone |
increases expression multiple interactions |
ISO |
niraparib results in increased expression of H2AX protein diphenyleneiodonium inhibits the reaction [niraparib results in increased expression of H2AX protein] |
CTD |
PMID:34396909 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
niraparib binds to and results in decreased activity of PARP1 protein |
CTD |
PMID:28001384 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Parp2 |
poly (ADP-ribose) polymerase 2 |
multiple interactions |
ISO |
niraparib binds to and results in decreased activity of PARP2 protein |
CTD |
PMID:28001384 |
|
NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338
|
|
|
G |
Ercc6 |
ERCC excision repair 6, chromatin remodeling factor |
multiple interactions affects response to substance |
ISO |
NU 1025 inhibits the reaction [ERCC6 gene mutant form results in increased abundance of Superoxides] ERCC6 gene mutant form affects the susceptibility to NU 1025 |
CTD |
PMID:25440059 |
|
NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
|
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
[Dietary Fats co-treated with olaparib] results in decreased expression of ACACA mRNA |
CTD |
PMID:27984176 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acacb |
acetyl-CoA carboxylase beta |
multiple interactions |
ISO |
[Dietary Fats co-treated with olaparib] results in decreased expression of ACACB mRNA |
CTD |
PMID:27984176 |
|
NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
ISO |
[Dietary Fats co-treated with olaparib] results in decreased expression of ACOX1 mRNA |
CTD |
PMID:27984176 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of ACTA2 mRNA] |
CTD |
PMID:27984176 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adgre1 |
adhesion G protein-coupled receptor E1 |
multiple interactions |
ISO |
olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of ADGRE1 mRNA] |
CTD |
PMID:27984176 |
|
NCBI chr 9:2,242,476...2,398,000
Ensembl chr 9:2,242,474...2,398,000
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
multiple interactions |
ISO |
olaparib inhibits the reaction [Methylmercury Compounds results in increased expression of AIFM1 protein] |
CTD |
PMID:35396826 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
olaparib promotes the reaction [Hydrogen Peroxide results in increased phosphorylation of AKT1 protein]; olaparib promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:30296409 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bap1 |
BRCA1 associated deubiquitinase 1 |
increases response to substance |
ISO |
BAP1 gene mutant form results in increased susceptibility to olaparib |
CTD |
PMID:22683710 |
|
NCBI chr16:6,446,709...6,455,535
Ensembl chr16:6,446,709...6,455,535
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
INCB054329 promotes the reaction [olaparib results in increased expression of BAX protein] |
CTD |
PMID:29567272 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
olaparib results in decreased expression of BCL2 protein |
CTD |
PMID:25531448 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
olaparib results in decreased expression of BIRC5 protein |
CTD |
PMID:25531448 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Brca1 |
BRCA1, DNA repair associated |
affects response to substance multiple interactions |
ISO |
BRCA1 affects the susceptibility to olaparib [BRD4 protein affects the susceptibility to olaparib] which affects the expression of BRCA1 protein; [olaparib co-treated with INCB054329] results in decreased expression of BRCA1 protein; olaparib promotes the reaction [INCB054329 results in decreased expression of BRCA1 protein] |
CTD |
PMID:21633166 PMID:29567272 |
|
NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304
|
|
G |
Brca2 |
BRCA2, DNA repair associated |
affects response to substance |
ISO |
BRCA2 affects the susceptibility to olaparib |
CTD |
PMID:21633166 |
|
NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567
|
|
G |
Brd4 |
bromodomain containing 4 |
multiple interactions affects response to substance |
ISO |
[BRD4 protein affects the susceptibility to olaparib] which affects the cleavage of PARP1 protein; [BRD4 protein affects the susceptibility to olaparib] which affects the expression of BRCA1 protein; [BRD4 protein affects the susceptibility to olaparib] which affects the expression of H2AX protein |
CTD |
PMID:29567272 |
|
NCBI chr 7:11,216,446...11,296,029
Ensembl chr 7:11,216,446...11,295,539
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[Fluorouracil co-treated with olaparib] results in increased cleavage of CASP3 protein; [olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Fluorouracil co-treated with olaparib] results in increased cleavage of CASP3 protein]; CASP8 protein affects the reaction [[olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein]; olaparib inhibits the reaction [Methylmercury Compounds results in increased cleavage of CASP3 protein] |
CTD |
PMID:25531448 PMID:26544897 PMID:35396826 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[Fluorouracil co-treated with olaparib] results in increased cleavage of CASP8 protein; [olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Fluorouracil co-treated with olaparib] results in increased cleavage of CASP8 protein]; CASP8 protein affects the reaction [[olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein] |
CTD |
PMID:25531448 PMID:26544897 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
[olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; olaparib inhibits the reaction [Methylmercury Compounds results in increased expression of CASP9 protein] |
CTD |
PMID:25531448 PMID:35396826 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
olaparib inhibits the reaction [Ethanol results in increased expression of CCL2 protein] |
CTD |
PMID:29317476 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
ISO |
olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of CCN2 mRNA] |
CTD |
PMID:27984176 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccne1 |
cyclin E1 |
multiple interactions |
ISO |
[olaparib co-treated with INCB054329] results in decreased expression of CCNE1 protein; olaparib promotes the reaction [INCB054329 results in decreased expression of CCNE1 protein] |
CTD |
PMID:29567272 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
multiple interactions |
ISO |
[Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of CCR2 mRNA |
CTD |
PMID:27984176 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO |
olaparib results in increased expression of CDKN1A protein INCB054329 promotes the reaction [olaparib results in increased expression of CDKN1A protein]; olaparib promotes the reaction [INCB054329 results in increased expression of CDKN1A protein] |
CTD |
PMID:29567272 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Chek1 |
checkpoint kinase 1 |
increases phosphorylation |
ISO |
olaparib results in increased phosphorylation of CHEK1 protein |
CTD |
PMID:25531448 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of COL1A1 mRNA] |
CTD |
PMID:27984176 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Ctcf |
CCCTC-binding factor |
decreases binding |
ISO |
olaparib decreases binding of CTCF to Cp promoter region in human lymphoblastoid cell lines |
RGD |
PMID:29976663 |
RGD:151356754 |
NCBI chr19:33,521,726...33,571,124
Ensembl chr19:33,529,319...33,571,123
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of CXCL2 mRNA; olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of CXCL2 mRNA] |
CTD |
PMID:27984176 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
ISO |
olaparib inhibits the reaction [Methylmercury Compounds results in increased expression of CYCS protein] |
CTD |
PMID:35396826 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
ISO |
DDIT3 protein affects the reaction [[TNFSF10 protein co-treated with olaparib] results in increased expression of TNFRSF10B protein] olaparib results in increased expression of DDIT3 protein |
CTD |
PMID:25531448 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
[Dietary Fats co-treated with olaparib] results in decreased expression of FASN mRNA |
CTD |
PMID:27984176 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fh |
fumarate hydratase |
increases response to substance |
ISO |
FH mutant form results in increased susceptibility to olaparib |
CTD |
PMID:30013182 |
|
NCBI chr13:87,524,331...87,550,215
Ensembl chr13:87,524,337...87,550,266
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
[Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of GPT protein; olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of GPT protein] |
CTD |
PMID:27984176 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions increases expression increases phosphorylation |
ISO |
(+)-JQ1 compound promotes the reaction [olaparib results in increased expression of H2AX protein]; [BRD4 protein affects the susceptibility to olaparib] which affects the expression of H2AX protein; [Fluorouracil co-treated with olaparib] results in increased phosphorylation of H2AX protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Fluorouracil co-treated with olaparib] results in increased phosphorylation of H2AX protein]; INCB054329 promotes the reaction [olaparib results in increased expression of H2AX protein]; olaparib promotes the reaction [(+)-JQ1 compound results in increased expression of H2AX protein]; olaparib promotes the reaction [INCB054329 results in increased expression of H2AX protein]; TP53 gene mutant form affects the reaction [benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Fluorouracil co-treated with olaparib] results in increased phosphorylation of H2AX protein]] olaparib results in increased phosphorylation of H2AX protein |
CTD |
PMID:25531448 PMID:26544897 PMID:29567272 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
EXP |
olaparib inhibits the reaction [Ethanol results in increased expression of HMGB1 protein] |
CTD |
PMID:29339456 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
[Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of ICAM1 mRNA |
CTD |
PMID:27984176 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of IL1B mRNA |
CTD |
PMID:27984176 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
olaparib inhibits the reaction [Ethanol results in increased expression of IL6 protein] |
CTD |
PMID:29317476 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO EXP |
Chloroquine promotes the reaction [olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; olaparib promotes the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; olaparib promotes the reaction [Chloroquine results in increased lipidation of MAP1LC3B protein] bafilomycin A1 inhibits the reaction [olaparib inhibits the reaction [Hydrogen Peroxide results in increased lipidation of MAP1LC3B protein]]; olaparib inhibits the reaction [Hydrogen Peroxide results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:34826546 PMID:36639873 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression multiple interactions |
ISO |
olaparib results in decreased expression of MKI67 protein INCB054329 promotes the reaction [olaparib results in decreased expression of MKI67 protein]; olaparib promotes the reaction [INCB054329 results in decreased expression of MKI67 protein] |
CTD |
PMID:29567272 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mlh1 |
mutL homolog 1 |
multiple interactions |
ISO |
olaparib inhibits the reaction [MLH1 protein results in decreased susceptibility to Floxuridine] |
CTD |
PMID:22194930 |
|
NCBI chr 8:111,196,468...111,233,721
Ensembl chr 8:111,196,468...111,233,617
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
[Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of MPO protein |
CTD |
PMID:27984176 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Msh2 |
mutS homolog 2 |
multiple interactions |
ISO |
olaparib inhibits the reaction [MSH2 protein results in decreased susceptibility to Floxuridine] |
CTD |
PMID:22194930 |
|
NCBI chr 6:6,813,793...6,872,960
Ensembl chr 6:6,813,795...6,872,938
|
|
G |
Msh3 |
mutS homolog 3 |
decreases response to substance |
ISO |
MSH3 protein results in decreased susceptibility to olaparib |
CTD |
PMID:21285347 |
|
NCBI chr 2:23,444,326...23,585,777
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage decreases binding decreases activity |
ISO |
olaparib inhibits the reaction [Hydrogen Peroxide results in increased activity of PARP1 protein] olaparib results in increased cleavage of PARP1 protein (+)-JQ1 compound promotes the reaction [olaparib results in increased cleavage of PARP1 protein]; [BRD4 protein affects the susceptibility to olaparib] which affects the cleavage of PARP1 protein; INCB054329 promotes the reaction [olaparib results in increased cleavage of PARP1 protein]; olaparib inhibits the reaction [Methylmercury Compounds results in increased cleavage of PARP1 protein]; olaparib promotes the reaction [INCB054329 results in increased cleavage of PARP1 protein] olaparib decreases binding of PARP1 to Cp promoter region in human lymphoblastoid cell lines olaparib results in decreased activity of PARP1 protein |
CTD RGD |
PMID:24814482 PMID:28001384 PMID:29567272 PMID:35396826 PMID:29976663 |
RGD:151356754 |
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Parp2 |
poly (ADP-ribose) polymerase 2 |
multiple interactions |
ISO |
olaparib binds to and results in decreased activity of PARP2 protein |
CTD |
PMID:28001384 |
|
NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions decreases expression |
ISO |
INCB054329 promotes the reaction [olaparib results in decreased expression of PCNA protein] |
CTD |
PMID:29567272 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pla2g2a |
phospholipase A2 group IIA |
multiple interactions |
EXP |
olaparib inhibits the reaction [Ethanol results in increased expression of PLA2G2A protein] |
CTD |
PMID:29339456 |
|
NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014
|
|
G |
Pla2g4a |
phospholipase A2 group 4A |
multiple interactions |
EXP |
olaparib inhibits the reaction [Ethanol results in increased expression of PLA2G4A protein] |
CTD |
PMID:29339456 |
|
NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
[Dietary Fats co-treated with olaparib] results in decreased expression of PPARA mRNA |
CTD |
PMID:27984176 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Rad51 |
RAD51 recombinase |
multiple interactions |
ISO |
[olaparib co-treated with INCB054329] results in decreased expression of RAD51 protein |
CTD |
PMID:29567272 |
|
NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035
|
|
G |
Sdhb |
succinate dehydrogenase complex iron sulfur subunit B |
increases response to substance |
ISO |
SDHB mutant form results in increased susceptibility to olaparib |
CTD |
PMID:30013182 |
|
NCBI chr 5:153,264,906...153,285,570
Ensembl chr 5:153,264,899...153,314,293
|
|
G |
Sirt1 |
sirtuin 1 |
increases expression multiple interactions |
ISO |
olaparib results in increased expression of SIRT1 protein olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein] |
CTD |
PMID:34826546 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
EXP |
olaparib inhibits the reaction [Hydrogen Peroxide results in decreased expression of SQSTM1 protein] |
CTD |
PMID:36639873 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
[Dietary Fats co-treated with olaparib] results in decreased expression of SREBF1 mRNA |
CTD |
PMID:27984176 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TGFB1 mRNA] |
CTD |
PMID:27984176 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
[Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of TNF mRNA; olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TNF mRNA]; olaparib inhibits the reaction [Ethanol results in increased expression of TNF protein] |
CTD |
PMID:27984176 PMID:29317476 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions |
ISO |
[olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; [olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; [olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; [TNFSF10 protein co-treated with olaparib] results in increased expression of TNFRSF10B protein; CASP8 protein affects the reaction [[olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [[TNFSF10 protein co-treated with olaparib] results in increased expression of TNFRSF10B protein] |
CTD |
PMID:25531448 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases phosphorylation |
ISO |
[Fluorouracil co-treated with olaparib] results in increased expression of TP53 protein; TP53 gene mutant form affects the reaction [benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Fluorouracil co-treated with olaparib] results in increased phosphorylation of H2AX protein]] olaparib results in increased phosphorylation of TP53 protein |
CTD |
PMID:25531448 PMID:26544897 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Xrcc1 |
X-ray repair cross complementing 1 |
multiple interactions |
ISO |
olaparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD] |
CTD |
PMID:35778544 |
|
NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701
|
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
multiple interactions |
ISO |
phenanthridone inhibits the reaction [Methylnitronitrosoguanidine results in increased localization of AIFM1 protein] |
CTD |
PMID:15589979 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
[eprenetapopt co-treated with phenanthridone] results in increased cleavage of CASP7 protein |
CTD |
PMID:29416738 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
[eprenetapopt co-treated with phenanthridone] results in increased cleavage of CASP9 protein |
CTD |
PMID:29416738 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
phenanthridone analog inhibits the reaction [endotoxin, Escherichia coli results in increased expression of CCL3 protein] |
CTD |
PMID:12006805 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Cd83 |
CD83 molecule |
decreases expression |
ISO |
phenanthridone results in decreased expression of CD83 mRNA; phenanthridone results in decreased expression of CD83 protein |
CTD |
PMID:17579050 |
|
NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083
|
|
G |
Cd86 |
CD86 molecule |
decreases expression |
ISO |
phenanthridone results in decreased expression of CD86 mRNA; phenanthridone results in decreased expression of CD86 protein |
CTD |
PMID:17579050 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
phenanthridone analog inhibits the reaction [endotoxin, Escherichia coli results in increased expression of CXCL2 protein] |
CTD |
PMID:12006805 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
H2ax |
H2A.X variant histone |
increases expression multiple interactions |
ISO |
phenanthridone results in increased expression of H2AX protein modified form Acetylcysteine inhibits the reaction [phenanthridone results in increased expression of H2AX protein modified form]; TXNRD1 protein inhibits the reaction [phenanthridone results in increased expression of H2AX protein modified form] |
CTD |
PMID:29416738 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Ifng |
interferon gamma |
multiple interactions decreases expression |
EXP |
phenanthridone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA] phenanthridone results in decreased expression of IFNG mRNA |
CTD |
PMID:12411406 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
phenanthridone inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein] |
CTD |
PMID:17579050 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
phenanthridone inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein] |
CTD |
PMID:17579050 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
EXP |
phenanthridone results in decreased expression of IL1B mRNA |
CTD |
PMID:12411406 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
decreases expression multiple interactions |
EXP |
phenanthridone results in decreased expression of IL2 mRNA phenanthridone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA] |
CTD |
PMID:12411406 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Kif18a |
kinesin family member 18A |
increases metabolic processing |
ISO |
phenanthridone results in increased metabolism of KIF18A protein |
CTD |
PMID:28209915 |
|
NCBI chr 3:95,764,388...95,824,756
Ensembl chr 3:95,764,388...95,824,582
|
|
G |
Kifc1 |
kinesin family member C1 |
increases metabolic processing |
ISO |
phenanthridone results in increased metabolism of KIFC1 protein |
CTD |
PMID:28209915 |
|
NCBI chr20:4,998,832...5,017,107
Ensembl chr20:4,999,047...5,017,105
|
|
G |
Nos2 |
nitric oxide synthase 2 |
decreases expression |
EXP |
phenanthridone results in decreased expression of NOS2 mRNA |
CTD |
PMID:12411406 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
decreases activity multiple interactions |
EXP ISO |
phenanthridone results in decreased activity of PARP1 protein [eprenetapopt co-treated with phenanthridone] results in increased cleavage of PARP1 protein |
CTD |
PMID:12411406 PMID:29416738 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
EXP |
phenanthridone results in decreased expression of PTGS2 mRNA |
CTD |
PMID:12411406 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
EXP ISO |
phenanthridone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of TNF mRNA] phenanthridone analog inhibits the reaction [endotoxin, Escherichia coli results in increased expression of TNF protein] phenanthridone results in decreased expression of TNF mRNA |
CTD |
PMID:12006805 PMID:12411406 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
multiple interactions decreases expression |
ISO |
TXNRD1 protein inhibits the reaction [phenanthridone results in increased expression of H2AX protein modified form] phenanthridone results in decreased expression of TXNRD1 mRNA; phenanthridone results in decreased expression of TXNRD1 protein |
CTD |
PMID:29416738 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
|
G |
Itgam |
integrin subunit alpha M |
decreases expression |
EXP |
PJ34 decreases expression of Itgam mRNA and protein in ischemic brain |
RGD |
PMID:23151666 |
RGD:329902065 |
NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
|
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
affects response to substance |
ISO |
BCL2L1 protein affects the susceptibility to rucaparib |
CTD |
PMID:32927276 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Brca1 |
BRCA1, DNA repair associated |
affects response to substance |
ISO |
BRCA1 protein affects the susceptibility to rucaparib |
CTD |
PMID:32927276 |
|
NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304
|
|
G |
Brd4 |
bromodomain containing 4 |
affects response to substance |
ISO |
BRD4 protein affects the susceptibility to rucaparib |
CTD |
PMID:32927276 |
|
NCBI chr 7:11,216,446...11,296,029
Ensembl chr 7:11,216,446...11,295,539
|
|
G |
Casp3 |
caspase 3 |
increases expression multiple interactions |
ISO |
rucaparib results in increased expression of CASP3 protein [Irinotecan co-treated with rucaparib] results in increased expression of CASP3 protein |
CTD |
PMID:30612311 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
rucaparib inhibits the reaction [Ethanol results in increased expression of CCL2 protein] |
CTD |
PMID:29317476 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
[rucaparib co-treated with Dasatinib] results in decreased expression of CCND1 protein |
CTD |
PMID:32927276 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdk9 |
cyclin-dependent kinase 9 |
affects response to substance |
ISO |
CDK9 protein affects the susceptibility to rucaparib |
CTD |
PMID:32927276 |
|
NCBI chr 3:15,996,467...16,001,315
Ensembl chr 3:15,996,468...16,002,410
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions affects expression |
ISO |
[Irinotecan co-treated with rucaparib] results in increased expression of H2AX protein; [rucaparib co-treated with CPI-0610] results in increased expression of H2AX protein; [rucaparib co-treated with Dasatinib co-treated with CPI-0610] results in increased expression of H2AX protein; [rucaparib co-treated with Dasatinib] results in increased expression of H2AX protein rucaparib affects the expression of H2AX protein |
CTD |
PMID:30612311 PMID:32927276 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
rucaparib inhibits the reaction [Ethanol results in increased expression of IL6 protein] |
CTD |
PMID:29317476 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
ISO |
[Irinotecan co-treated with rucaparib] results in decreased expression of MKI67 protein |
CTD |
PMID:30612311 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions decreases expression |
ISO |
[rucaparib co-treated with Dasatinib co-treated with CPI-0610] results in increased cleavage of PARP1 protein; rucaparib binds to and results in decreased activity of PARP1 protein; rucaparib inhibits the reaction [Irinotecan results in increased expression of PARP1 protein]; rucaparib promotes the reaction [navitoclax results in increased cleavage of PARP1 protein] rucaparib results in decreased expression of PARP1 protein |
CTD |
PMID:28001384 PMID:30612311 PMID:32927276 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Parp2 |
poly (ADP-ribose) polymerase 2 |
decreases activity |
ISO |
rucaparib results in decreased activity of PARP2 protein |
CTD |
PMID:28001384 |
|
NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
[Irinotecan co-treated with rucaparib] results in decreased expression of RPS6KB1 protein |
CTD |
PMID:30612311 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
affects response to substance multiple interactions increases phosphorylation |
ISO |
SRC protein affects the susceptibility to rucaparib [rucaparib co-treated with Dasatinib] results in decreased phosphorylation of SRC protein rucaparib results in increased phosphorylation of SRC protein |
CTD |
PMID:32927276 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
rucaparib inhibits the reaction [Ethanol results in increased expression of TNF protein] |
CTD |
PMID:29317476 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnks2 |
tankyrase 2 |
affects binding |
ISO |
rucaparib binds to TNKS2 protein |
CTD |
PMID:28001384 |
|
NCBI chr 1:234,567,888...234,621,079
Ensembl chr 1:234,567,858...234,621,079
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases transport |
ISO |
ABCB1 protein results in increased transport of veliparib |
CTD |
PMID:21436403 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
veliparib promotes the reaction [Hydrogen Peroxide results in increased phosphorylation of AKT1 protein]; veliparib promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:30296409 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions increases activity |
ISO |
veliparib results in increased phosphorylation of and results in increased activity of ATM protein veliparib results in increased activity of ATM protein |
CTD |
PMID:21917757 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions |
ISO |
BAK1 protein results in increased susceptibility to [Methylnitronitrosoguanidine co-treated with veliparib] |
CTD |
PMID:18376143 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
BAX protein results in increased susceptibility to [Methylnitronitrosoguanidine co-treated with veliparib] |
CTD |
PMID:18376143 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
BCL2L1 protein results in decreased susceptibility to [Methylnitronitrosoguanidine co-treated with veliparib] |
CTD |
PMID:18376143 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Brca1 |
BRCA1, DNA repair associated |
affects response to substance decreases response to substance |
ISO |
BRCA1 affects the susceptibility to veliparib BRCA1 protein results in decreased susceptibility to veliparib |
CTD |
PMID:21633166 PMID:21707865 |
|
NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304
|
|
G |
Brca2 |
BRCA2, DNA repair associated |
affects response to substance |
ISO |
BRCA2 affects the susceptibility to veliparib |
CTD |
PMID:21633166 |
|
NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567
|
|
G |
Cdk12 |
cyclin-dependent kinase 12 |
affects response to substance |
ISO |
CDK12 protein affects the susceptibility to veliparib |
CTD |
PMID:27880910 |
|
NCBI chr10:83,201,177...83,256,906
Ensembl chr10:83,201,211...83,280,888 Ensembl chr10:83,201,211...83,280,888
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases metabolic processing |
ISO |
CYP1A2 protein results in increased metabolism of veliparib |
CTD |
PMID:21436403 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
increases metabolic processing |
ISO |
CYP2C19 protein results in increased metabolism of veliparib |
CTD |
PMID:21436403 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
increases metabolic processing |
ISO |
CYP2D6 protein results in increased metabolism of veliparib |
CTD |
PMID:21436403 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases metabolic processing |
ISO |
CYP3A4 protein results in increased metabolism of veliparib |
CTD |
PMID:21436403 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases response to substance affects localization |
ISO |
EGFR protein results in decreased susceptibility to veliparib veliparib affects the localization of EGFR protein |
CTD |
PMID:21719137 PMID:21912620 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Ercc1 |
ERCC excision repair 1, endonuclease non-catalytic subunit |
multiple interactions |
ISO |
ERCC1 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]] |
CTD |
PMID:21227924 |
|
NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963
|
|
G |
Ercc4 |
ERCC excision repair 4, endonuclease catalytic subunit |
multiple interactions |
ISO |
ERCC4 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]] |
CTD |
PMID:21227924 |
|
NCBI chr10:2,416,259...2,448,364
Ensembl chr10:2,419,038...2,448,369
|
|
G |
Ercc6 |
ERCC excision repair 6, chromatin remodeling factor |
multiple interactions |
ISO |
veliparib promotes the reaction [ERCC6 protein affects the susceptibility to potassium bromate] |
CTD |
PMID:25136123 |
|
NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions increases expression |
ISO |
[veliparib co-treated with Topotecan] results in increased expression of H2AX protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; ERCC1 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; ERCC4 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; TDP1 protein inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; veliparib inhibits the reaction [PARP1 protein mutant form results in increased expression of H2AX protein modified form]; veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein] [veliparib results in increased expression of PARP1 protein] which results in increased expression of H2AX protein; veliparib results in increased expression of H2AX protein; veliparib results in increased expression of H2AX protein modified form |
CTD |
PMID:17505006 PMID:21227924 PMID:21795476 PMID:21917757 PMID:27694308 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
veliparib inhibits the reaction [S100B protein results in increased expression of IL1B mRNA] |
CTD |
PMID:27444121 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Mpg |
N-methylpurine-DNA glycosylase |
multiple interactions |
ISO |
MPG protein promotes the reaction [veliparib results in increased susceptibility to temozolomide] |
CTD |
PMID:21377995 |
|
NCBI chr10:15,396,246...15,402,528
Ensembl chr10:15,395,782...15,402,520
|
|
G |
Mre11 |
MRE11 homolog, double strand break repair nuclease |
decreases response to substance |
ISO |
MRE11 protein results in decreased susceptibility to veliparib |
CTD |
PMID:21300766 |
|
NCBI chr 8:11,618,876...11,680,451
Ensembl chr 8:11,632,354...11,678,279
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
veliparib inhibits the reaction [S100B protein results in increased expression of NOS2 mRNA] |
CTD |
PMID:27444121 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions decreases activity increases expression |
ISO |
PARP1 protein affects the susceptibility to [Temozolomide co-treated with veliparib]; veliparib binds to and results in decreased activity of PARP1 protein; veliparib inhibits the reaction [Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]]; veliparib inhibits the reaction [PARP1 protein mutant form affects the abundance of NAD]; veliparib inhibits the reaction [PARP1 protein mutant form results in increased expression of H2AX protein modified form]; veliparib inhibits the reaction [PARP1 protein mutant form results in increased expression of RPA2 protein modified form] veliparib results in decreased activity of PARP1 protein [veliparib results in increased expression of PARP1 protein] which results in increased expression of H2AX protein; veliparib results in increased expression of PARP1 protein; veliparib results in increased expression of PARP1 protein mutant form [veliparib results in decreased activity of PARP1 protein] which results in increased susceptibility to Camptothecin |
CTD |
PMID:17505006 PMID:19143569 PMID:19823047 PMID:19825992 PMID:21300766 PMID:21917757 PMID:22041887 PMID:22158865 PMID:27694308 PMID:28001384 More...
|
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Parp10 |
poly (ADP-ribose) polymerase family, member 10 |
affects binding |
ISO |
veliparib binds to PARP10 protein |
CTD |
PMID:28001384 |
|
NCBI chr 7:107,949,031...107,958,377
Ensembl chr 7:107,949,043...107,958,304
|
|
G |
Parp2 |
poly (ADP-ribose) polymerase 2 |
affects binding multiple interactions decreases activity |
ISO |
PARP2 protein binds to veliparib veliparib binds to and results in decreased activity of PARP2 protein veliparib results in decreased activity of PARP2 protein |
CTD |
PMID:19143569 PMID:20092359 PMID:21917757 PMID:28001384 |
|
NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338
|
|
G |
Pten |
phosphatase and tensin homolog |
decreases response to substance |
ISO |
PTEN protein results in decreased susceptibility to veliparib |
CTD |
PMID:20530668 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Rpa2 |
replication protein A2 |
multiple interactions |
ISO |
veliparib inhibits the reaction [PARP1 protein mutant form results in increased expression of RPA2 protein modified form] |
CTD |
PMID:27694308 |
|
NCBI chr 5:144,976,789...144,989,445
Ensembl chr 5:144,976,748...144,987,350
|
|
G |
S100b |
S100 calcium binding protein B |
multiple interactions |
ISO |
veliparib inhibits the reaction [S100B protein results in increased expression of IL1B mRNA]; veliparib inhibits the reaction [S100B protein results in increased expression of NOS2 mRNA] |
CTD |
PMID:27444121 |
|
NCBI chr20:12,372,866...12,381,619
Ensembl chr20:12,372,881...12,394,743
|
|
G |
Tdp1 |
tyrosyl-DNA phosphodiesterase 1 |
multiple interactions |
ISO |
TDP1 protein inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]] |
CTD |
PMID:21227924 |
|
NCBI chr 6:119,163,192...119,231,029
Ensembl chr 6:119,163,166...119,231,021
|
|
G |
Xrcc1 |
X-ray repair cross complementing 1 |
multiple interactions |
ISO |
veliparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD] |
CTD |
PMID:35778544 |
|
NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701
|
|